公开(公告)号：US20120004251A1

公开(公告)日：2012-01-05

申请号：US13075873

申请日：2011-03-30

申请人： Ben Whalley ,  Claire Williams ,  Gary Stephens ,  Takashi Futamura

发明人： Ben Whalley ,  Claire Williams ,  Gary Stephens ,  Takashi Futamura

IPC分类号： A61K31/515 ,  A61P25/08 ,  A61K31/4015 ,  A61K31/19 ,  A61K31/05 ,  A61K31/352

CPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/352 ,  A61K31/40 ,  A61K31/515 ,  A61K36/185 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

摘要翻译： 本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。 本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。 优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

公开(公告)号：US09125859B2

公开(公告)日：2015-09-08

申请号：US13075873

申请日：2011-03-30

申请人： Ben Whalley ,  Claire Williams ,  Gary Stephens ,  Takashi Futamura

发明人： Ben Whalley ,  Claire Williams ,  Gary Stephens ,  Takashi Futamura

IPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/352 ,  A61K31/40 ,  A61K36/185 ,  A61K45/06

CPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/352 ,  A61K31/40 ,  A61K31/515 ,  A61K36/185 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.

摘要翻译： 本发明涉及植物大麻素大麻素（CBDV）和植物大麻素CBDV与四氢大麻素（THCV）和大麻二醇（CBD）的组合在治疗癫痫中的用途。 本发明还涉及植物大麻素CBDV与标准抗癫痫药（SAED）的组合的用途。 优选地，SAED是乙酰亚胺，丙戊酸盐或苯巴比妥之一。

公开(公告)号：US09066920B2

公开(公告)日：2015-06-30

申请号：US13380305

申请日：2010-06-29

申请人： Ben Whalley ,  Gary Stephens ,  Claire Williams ,  Geoffrey Guy ,  Stephen Wright ,  Tetsuro Kikuchi

发明人： Ben Whalley ,  Gary Stephens ,  Claire Williams ,  Geoffrey Guy ,  Stephen Wright ,  Tetsuro Kikuchi

IPC分类号： A61K31/352 ,  A61K31/05

CPC分类号： A61K31/05 ,  A61K31/352

摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

摘要翻译： 本发明涉及一种或多种大麻素用于治疗癫痫的用途，更具体地说涉及使用一种或大麻素的组合来治疗广泛性或部分性发作。 在一个实施方案中，其涉及大麻素THCV作为纯的或分离的化合物或作为其中显着量的任何THC天然存在的植物提取物的使用已被选择性地除去。 在另一个实施方案中，植物大麻素是CBD。

公开(公告)号：US20130296398A1

公开(公告)日：2013-11-07

申请号：US13977766

申请日：2012-01-03

申请人： Ben Whalley ,  Claire Williams ,  Gary Stephens

发明人： Ben Whalley ,  Claire Williams ,  Gary Stephens

IPC分类号： A61K31/05 ,  A61K31/4015 ,  A61K31/19 ,  A61K45/06

CPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/515 ,  A61K36/00 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

摘要翻译： 本发明涉及以大于300mg /天的剂量与通过钠或钙通道作用的标准抗癫痫药（SAED）组合的大麻二酚（CBD）的用途，用于治疗癫痫 。 SAED优选是修饰低阈值或瞬时神经元钙电流，或者降低高频神经元激发和钠依赖性动作电位并增强GABA作用。 优选的SAED是乙酰亚胺和丙戊酸。

公开(公告)号：US20140155456A9

公开(公告)日：2014-06-05

申请号：US13977766

申请日：2012-01-03

申请人： Ben Whalley ,  Claire Williams ,  Gary Stephens

发明人： Ben Whalley ,  Claire Williams ,  Gary Stephens

IPC分类号： A61K31/05 ,  A61K31/4015 ,  A61K31/19 ,  A61K45/06

CPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/352 ,  A61K31/4015 ,  A61K31/515 ,  A61K36/00 ,  A61K45/06 ,  A61K2300/00

摘要： The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

摘要翻译： 本发明涉及以大于300mg /天的剂量与通过钠或钙通道作用的标准抗癫痫药（SAED）组合的大麻二酚（CBD）的用途，用于治疗癫痫 。 SAED优选是修改低阈值或瞬时神经元钙电流，或者降低高频神经元激发和钠依赖性动作电位并增强GABA效应。 优选的SAED是乙酰亚胺和丙戊酸。

公开(公告)号：US20140243405A1

公开(公告)日：2014-08-28

申请号：US14345968

申请日：2012-09-14

申请人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens

发明人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens

IPC分类号： A61K31/05 ,  A61K31/353 ,  A61K45/06

摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.

摘要翻译： 本发明涉及包含或基本上由植物大麻素大麻素（CBDV）和大麻二酚（CBD）组成的药物组合物。 该组合物特别安全和有效地用于治疗神经系统疾病，其特征在于中枢神经系统的兴奋性高，惊厥或惊厥如癫痫发作。 优选地，CBDV和CBD存在至少一种大麻素的非大麻素成分，例如一种或多种萜烯或萜烯级分。 更具体地，组合物还包含一种或多种大麻染料型化合物。 特别是异丙基丙基变体（CBCV）和/或大麻色素（CBC）。 更具体地，组合物不存在或基本上不含其他大麻素，包括特别是四氢大麻酚（THC）和四氢大麻素（THCV），其通常以大量化学型存在，以含有显着量的CBDV和/或CBD 。

公开(公告)号：US10729665B2

公开(公告)日：2020-08-04

申请号：US14345968

申请日：2012-09-14

申请人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

发明人： Benjamin Whalley ,  Claire Williams ,  Gary Stephens ,  Thomas Hill

IPC分类号： A61K31/352 ,  A61K31/05 ,  A61K36/185 ,  A61K31/045 ,  A61K31/353 ,  A61K45/06

摘要： This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC). More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and/or CBD.